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The concept of quality by design in the pharmaceutical field requires better control
of drug formulation and manufacturing processes (1) to ensure robust and predictable
outcomes. To circumvent these limitations, there is emerging interest in using mathema-
tical methods to better predict drug formulations (2). To contribute to this knowledge
gap in the field, specifically for drug nanoencapsulation, this study reports on the appli-
cation of statistical analysis to elucidate the features of heparin-loaded nanoparticles.
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The objective of this study was to use Box-Behnken de-
sign (BBD) to investigate the influence of formulation vari-
ables on the properties of heparin-loaded poly(lactic-co-
-glycolic acid) (PLGA)-polymethacrylate-RLPO (E-RLPO)
nanoparticles (NP) in terms of mean diameter (as size)
and drug encapsulation efficiency. The NPs were prepa-
red by the double emulsion solvent evaporation method.
The independent variables were: X1 – polymer mass ra-
tio (PLGA:E-RLPO) in the oil phase, X2 – concentration
of polyvinyl alcohol (PVA) as emulsion stabilizer, and X3
– volume of the external aqueous phase (W2). Particle si-
ze (analyzed by dynamic light scattering) and encapsu-
lation efficiency (EE, estimated by spectrophotometry)
were the investigated responses. The polynomial equa-
tion obtained from regression analysis of the reduced
model (p = 0.0002, F = 25.7952 and R2 = 0.96) provided
an excellent fit. The optimal size for the NP was found
to be 134.2 ± 16.5 nm with formulation variables of
48.2:61.8, 0.321 (%, m/V) and 263 mL for X1, X2 and X3,
respectively. Probably, due to electrostatic interaction be-
tween the negatively charged drug and the positively
charged E-RLPO, the percent EE of heparin was between
74.4 ± 6.5 % (lowest value) and 92.1 ± 5.3 % (highest va-
lue). The data suggest that BBD is a useful tool in ratio-
nal design of heparin-loaded NPs.
Keywords: heparin, nanoparticle, encapsulation efficien-
cy, Box-Behnken design
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Heparin is a water soluble, negatively charged molecule belonging to the group of
glycoso-aminoglycans. Its anticoagulant action is well established (3). After injection,
heparin chains enter a cellular pool and effectively prevent thrombosis by increasing the
electronegative potential of the vessel wall (4). Low-molecular-mass heparins (LMWH’s)
are heparin salts having an average molecular mass of less than 8000 Da. Heparin is still
essentially administered in clinics by injections, which presents several limitations for
effective pharmacotherapy of thrombosis. To overcome these limitations, a non-invasive
and improved heparin delivery system may be needed to enhance patient compliance
and minimize adverse effects (5). Alternative for heparin delivery, which are under re-
search include the pulmonary route (6) that offers many advantages. Considering the
above aspects and the urgent need for an alternative route for heparin, the long-term
goal of this research endeavour is to formulate heparin-loaded nanoparticles for pulmo-
nary delivery. In pursuit of that goal, the immediate objective of this study was to opti-
mize heparin nanoencapsulation with a polymeric matrix using the double-emulsion
solvent-evaporation method.
A 3-factor, 3-level Box-Behnken design (BBD) was employed to design experiments
based on the response surface methodology (7). The design specified low, medium, and
high values for the chosen variables. BBD is an efficient experimental design method,
because it involves fewer experiments compared to a full factorial design. In this study,
the influence of independent variables, such as polymer ratio, stabilizer concentration




Polymethacrylate EudragitTM or EudragitC RLPO (E-RLPO) was purchased from
Röhm Pharma GmbH (Germany). Poly(DL-lactide-co-glycolide) (PLGA) with inherent
viscosity (inh = ln rel/c, natural logarithm of the ratio between relative viscosity, rel
and polymeric dispersion concentration, c of 1.08 dL g–1 at 30 °C and a lactide-to-gly-
colide ratio of 50:50 was obtained from Birmingham Polymers, Inc. (USA). Polyvinyl al-
cohol (PVA) (Mr 30–70 kDa) and Azure-II dye were purchased from Sigma (USA). Meth-
ylene chloride (Fischer Scientific, USA), low-molecular-mass heparin (LMWH, lot # PH
61807 @ 170 IU mg–1) (Celsus, USA), and all other chemicals were of analytical grade
and were used without further purification.
Experimental design
The experimental design and analysis of the results were performed using the JMP
version 5.1 software (SAS Institute, USA). The 3-factor, 3-level BBD was used to opti-
mize the particle size and percent encapsulation of the drug. The number of experiments
(N) required was determined using the following equation (7):
N = (2k)(k – 1) + C0 (1)
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where k is the number of factors and C0 is the number of central points. In this study,
three factors (k = 3) and three central points (C0 = 3) were considered, providing a total
of 15 experiments according to Eq. (1). The independent variables are defined in Table I.
Based on the analysis of the data and the model obtained after multiple regression, a
polynomial equation was predicted defining the optimized nanoparticles in terms of the
least diameter size (after freeze drying) and maximum heparin encapsulation.
Preparation of heparin-loaded nanoparticles
LMWH-loaded nanoparticles were prepared by an adapted multiple emulsion
(w/o/w) technique (8). In this, 1 mL of an aqueous heparin solution (5000 IU) was first
emulsified in methylene chloride (10 mL) containing 0.5 g of the polymers by sonication
(VWR, USA) for 1 min at 60 W. The resulting water-in-oil (w/o) emulsion was poured
into an aqueous solution containing PVA, and mixed in a homogenizer (Ultra Turrax,
T-25 basic, USA) for 3 min. This formed the secondary water-in-oil-in-water (w/o/w)
emulsion. The organic solvent was removed at room temperature (32–37 °C) with con-
tinuous magnetic stirring for 2 hours. The emulsion was centrifuged at 20,000 rpm (29,
100xg) for 60 min, washed three times with water to remove excess PVA, and then dried
in a freeze-dryer (Labconco Co., USA). Samples were taken for particle size analysis be-
fore and after the freeze-drying. The supernatant collected after centrifugation was ana-
lyzed for heparin, and the encapsulation efficiency (EE) was calculated.
Characterization of nanoparticles
Particle size. – Particle size was measured by differential light scattering (DLS) (Brook-
haven Instruments Corp., USA) with the 90 Plus particle-sizing software (version 3.78).
Typically, 1–2 mL of the appropriately diluted sample was measured in triplicate. In or-
der to evaluate the effect of the drying process on the NP, samples were measured before
and after the freeze-drying.
Morphology analysis. – Surface features of the NP were analyzed using scanning elec-
tron microscopy (SEM) (FEI Co., USA). Samples of NP were fixed on supports with car-
bon-glue, and coated with gold–palladium under an argon atmosphere using a gold
sputter module in a high-vacuum evaporator. The morphology of the samples was ob-
served with XL-30, ESEM-FEG (FEI Co.).
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Polymer ratio (PLGA:E-RLPO) 20:80 50:50 80:20
PVA (%, m/V) 0.1 0.3 0.5
External phase volume (mL) 100 200 300
Determination of drug encapsulation efficiency. – The supernatant recovered by centri-
fugation during washing of the NPs was assayed using spectrophotometry (Genesys 10
Bio, Thermo Electron Co., USA) after appropriate dilution (9). A standard curve was first
plotted with heparin in the concentration range 1–5 IU mL–1. Typically, an aliquot of 0.5
mL of aqueous heparin solution, or the supernatant from NP preparation, was reacted with
4.5 mL of Azure II solution (0.01 mg mL–1) at room temperature and assayed at 530 nm.
Experiments were conducted in triplicate. Mean values and standard deviations were
calculated for each sample. Heparin concentration (IU mL–1) was determined from the
standard curve using values for the slope and intercept (0.0185 mL IU–1 and 0.0057, res-
pectively, R = 0.9939). The drug entrapment efficiency was expressed as the percentage
of heparin entrapped compared to the theoretical value.
RESULTS AND DISCUSSION
Particle size analysis
Heparin-loaded nanoparticles ranging from 150–875 nm were prepared after freeze-
-drying (Table II) using the 15-set of experiments of the BBD. As shown in Table II, the
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1 0+– 50:50 0.5 100 221.1 391.3 ± 33.9 82.5 ± 1.6
2 +0– 80:20 0.3 100 334.7 589.2 ± 50.9 75.1 ± 8.9
3 ++0 80:20 0.5 200 446.0 346.5 ± 21.2 74.4 ± 6.5
4 –0+ 20:80 0.3 300 190.1 194.8 ± 65.1 87.3 ± 7.5
5 000 50:50 0.3 200 277.3 211.5 ± 35.4 87.7 ± 5.7
6 0– – 50:50 0.1 100 743.4 875.7 ± 91.9 89.4 ± 6.6
7 – –0 20:80 0.1 200 373.4 602.1 ± 53.7 92.1 ± 5.3
8 0++ 50:50 0.5 300 469.1 301.2 ± 33.9 81.1 ± 7.9
9 –+0 20:80 0.5 200 196.9 150.4 ± 17.0 91.1 ± 4.1
10 +–0 80:20 0.1 200 271.4 348.5 ± 45.3 77.9 ± 8.3
11 0–+ 50:50 0.1 300 344.5 252.4 ± 53.7 87.5 ± 9.5
12 000 50:50 0.3 200 209.2 165.0 ± 22.6 88.5 ± 6.7
13 +0+ 80:20 0.3 300 235.6 210.4 ± 19.8 90.1 ± 0.1
14 –0– 20:80 0.3 100 286.8 416.0 ± 41.0 80.1 ± 6.8
15 000 50:50 0.3 200 224.1 213.6 ± 14.1 82.5 ± 5.8
a Pattern: (–) low, (0) medium, (+) high (Table I).
b Volume of the external water phase in the w/o/w emulsion.
c Diameter and EE are mean values ± SD (n = 3).
low levels of PVA and external aqueous phase volume (Table I) resulted in large heparin-
-loaded particles with a mean diameter of 875 ± 92 nm. On the other hand, the high level
of PVA (0.5 %, m/V), medium level of external phase volume (200 mL), and low level of
PLGA:E-RLPO polymer ratio (20:80) provided the smallest particle size (150 ± 17 nm).
These factors, affecting the size range of the NPs, are discussed in detail in the sections
below.
Morphological analysis
Surface morphology studies of the heparin-loaded nanoparticles of the different sets
of BBD batches showed variation in size consistent with the results in Table II. Figs. 1a
and 1b show typical SEM pictures of the small- and large-sized nanoparticles produced
by BBD experiments in batches 9 and 6, respectively.
In some of the SEM pictures, the remnants of PVA are clearly visible in the form of a
mesh-like structure. Repeated washings have removed most of the PVA from the NPs.
Fig. 1c shows typical PVA-containing NPs before the washing steps. Heparin-loaded
NPs are not clearly visible under the SEM due to the PVA covering layers. Indeed, it has
been shown that some amount of the PVA is always found to be associated with poly-
mer nanoparticles, even after repeated washings (10). After washing, the heparin-loaded
NPs appeared to be smooth, spherical and nonporous in both isolated and aggregated
forms (Fig. 1).
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Fig. 1. SEM of heparin-loaded nanopar-
ticles: a) small-sized nanoparticles (batch
No. 9, Table II), b) large-sized nanoparti-
cles (batch No. 6, Table II), c) heparin-






The drug encapsulation efficiency (EE) of the nanoparticles was remarkably high,
ranging from 74.4 ± 8.9 % (batch No. 3) to 92.1 ± 5.3 % (batch No. 7) (Table II). This also
suggests that the system in the present experimental setup was robust with respect to
the percentage of drug encapsulated. The narrow range over which the EE varied for the
system was mainly due to incorporation of the positively charged E-RLPO, which took
part in an electrostatic interaction with the negatively charged heparin macromolecules
(11).
Analysis of experimental data
Data obtained for the size and encapsulation efficiency based on the fifteen BBD ex-
periments (Table II) were analyzed as shown in Figs. 2–4 by depicting Pareto plots and
contour profiles, and examining the regression model parameter estimates residual
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Fig. 2. Residuals vs. predicted particle size of the heparin-loaded nanoparticles:
a) full model, b) reduced model.
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Fig. 3. Standardized Pareto chart for the particle size of heparin-loaded nanoparticles after
freeze-drying. Independent variables: X1 – polymer mass ratio (PLGA: E-RLPO) in the oil phase; X2
– concentration of polyvinyl alcohol (PVA %, m/V) as emulsion stabilizer; and X3 – volume of the
external aqueous phase (mL) and their corresponding interaction. Statistical significance level (p =
0.05) is indicated by the vertical line.
plots. Except for batches 1, 2, 7 and 14, there was a good correlation between the size of
heparin-loaded NPs before and after freeze-drying (Table II), suggesting that there was
no need to use cryoprotectants for this type of nanoparticles. Abdelwahed et al. (12) de-
scribed the stabilization of nanocapsule reservoir systems using 5 % PVA as a
cryoprotectant. In this study, the concentration of PVA in the heparin-loaded NP was
usually less than 0.5 %. The reasons why these four samples exhibited dramatic in-
creases in size during freeze-drying remain to be elucidated.
The encapsulation efficiency of the NPs was above 75 % (Table II), which is consid-
ered acceptable for all levels of independent variables (Table I). Hence, the variables
were optimized for particle size as described below.
Multiple regression analysis was performed using particle size as the response vari-
able and polymer ratio (PLGA: E-RLPO), concentration of PVA (%, m/V), and volume of
the external aqueous phase as independent variables. A polynomial equation determin-
ing the nanoparticle size was obtained based on the regression analysis, resulting in a
model that predicted the size of heparin-loaded nanoparticles. Eq. (2) incorporates indi-
vidual as well as combined effects of the independent variables:
Y = 191.1 + 16.4X1– 111.2X2 – 164.2X3 + 112.4X1X2 – 39.4X1X3 +
+ 133.3X2X3 + 34.2X12 + 136.7X22 + 127.4X32 (2)
where, Y is the partical size, X1 is the percentage polymer ratio, X2 is the concentration
of PVA (%, m/V), and X3 is the volume of the external aqueous phase (mL) (Table I). It is
important to underscore that in this study, the total amount/mass of polymer used to
form the NP matrix is constant. Only the relative proportion of PLGA to E-RLPO is the
variable in this context. In this constant amount of polymer mixture, defining the mass
or mass percentage of one polymer will automatically set the value for the second poly-
mer. This reduces the percentage polymer ratio into a single factor. For example, a per-
centage ratio of 50:50 means that the polymeric portion contains by mass 50 % of each
type of polymer and indeed corresponds to a standard ratio of 1:1. From the regression
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Fig. 4. Contour plot of the particle size (nm)
as the function of external phase volume
and PVA concentration. Polymer ratio was
kept constant at the center point.
analysis, the predicted values, residuals and standard errors for particle size were calcu-
lated and are shown in Table III. The R2 value for the model was found to be 0.98, indi-
cating an excellent fit to the data. Nevertheless, analysis of the data showed that the co-
efficients of interactions, namely polymer ratio ´ polymer ratio (X12), and polymer ratio ´
external volume (X1X3), were not statistically significant. Therefore, these interaction
terms were omitted from the final model. This omission was justified by performing the
following three different analyses:
(i) Regression analysis of the reduced model was performed and the p (0.0002), F
(25.7952) and R2 (0.96) values (Table IV) verified an excellent fit. The above values were
highly significant, justifying the omission of insignificant parameters.
(ii) Plot of residual vs. predicted values showed no correlation of data for either full
(Fig. 2a) or reduced models (Fig. 2b).
(iii) Regression analysis for the residuals obtained in both full and reduced models
was performed to justify the omission of insignificant interaction terms for obtaining a
reduced polynomial equation.
The above tests justified the omission of insignificant parameters. The reduced po-
lynomial equation was derived as shown below:
Y = 212.1 + 16.4X1 – 111.2X2 – 164.2X3 + 112.4X1X2 + 133.3X2X3 +
+ 134.1X22 + 124.8X32 (3)
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1 391.3 ± 33.9 374.8 +16.5 23.9
2 589.2 ± 50.9 572.5 +16.7 35.8
3 346.5 ± 21.2 379.5 –33.0 15.0
4 194.8 ± 65.1 211.4 –16.6 45.9
5 211.5 ± 35.4 196.7 +14.8 25.1
6 875.7 ± 91.9 863.7 +12.0 64.8
7 602.1 ± 53.7 569.0 +33.1 37.9
8 301.2 ± 33.9 313.1 –11.9 23.0
9 150.4 ± 17.0 121.8 +28.6 12.1
10 348.5 ± 45.3 377.0 –28.5 31.8
11 252.4 ± 53.7 268.8 –16.4 37.9
12 165.0 ± 22.6 196.7 –31.7 15.9
13 210.4 ± 19.8 165.4 +45.0 14.1
14 416.0 ± 41.0 460.9 –44.9 29.3
15 213.6 ± 14.1 196.7 +16.9 9.9
a Mean ± SD, n = 3.
b Residual: observed diameter (nm) – predicted diameter (nm)
where Y is the praticle size, X1, X2 and X3 are the same variables as defined above. The
R2 value for Eq. (3) was 0.96, which shows excellent fit, and the fit of the reduced model
was not significantly different from that of the initial model as shown in Table IV by cal-
culated F (FCAL(5, 7) = 2.46, p = 0.14). This table also indicates that the data fits to the re-
duced model as well. C1 is the sum of squares of the residuals (error) of the full model;
C2 is the sum of squares of the residuals (error) of the reduced model, D1 is the mean
square of the error of the full model, NTO is the number of terms omitted (which is 2).
On closer analysis, it appears that both the concentration of PVA (%, m/V) (X2) and the
external phase volume (X3) have a quadratic effect on particle size when other variables
are held constant, where particle size is minimized at the medium level of each. In addi-
tion, PVA concentration has a moderating effect on the relationship between the poly-
mer ratio and particle size, where the high level of concentration adds 112.4 nm to the ef-
fect of polymer ratio, and the low level subtracts 112.4 nm, when the volume of the
external phase is held constant. Concentration of PVA also had a moderating effect on
the relationship between the volume of the external phase and particle size, where the
high level of concentration adds 133.3 nm to the effect of the external phase on particle
size, and the low level subtracts 133.3 nm when the polymer ratio is held constant.
Pareto plots. – Pareto plots (Fig. 3) show the particle size varying curvilinearly with
the volume of the external phase (X3) and the PVA concentration, the emulsifier (X2) in-
dicating that at extremely low and extremely high values of these independent varia-
bles, it is possible to achieve maximum values for the response. Since the response un-
der consideration is particle size, we should aim at medium values to obtain the smallest
particle size, which is the ultimate objective of this work.
Contour profile. – To further elucidate the results from the Pareto plots, the contour
profiles X2 vs. X3 were plotted (Fig. 4). The contour profile predicted the particle size of
the heparin-loaded NPs to curvilinearly change with the two factors, PVA concentration
and the volume of the external phase. The third factor, the polymer ratio, was kept con-
stant at the medium value. As shown in Fig. 4, the smallest size of heparin-loaded NPs
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Model 7 530508.16 75786.9 25.7952 0.0002
Error 7 20566.15 (C2) 2938.0
Corrected total 14 551074.32
Full model
Model 9 565078.15 62786.5 30.3021 0.0009
Error 5 10360.08 (C1) 2072.0 (D1)
Corrected total 14 575438.24
a Probability of obtaining F-value greater than calculated.
FCAL = [(C2 – C1)/NTO]/D1 = 2.46 (df1 = 5, df2 = 7, p = 0.14), where NTO is the number of terms omitted.
(150 nm) was obtained with PVA concentration in the range of 0.25–0.4 %, (m/V), and the
external phase volume varying from 225–290 mL. Considering all the above observa-
tions, we concluded that the best values for obtaining the smallest particle size would be
around the medium value of the PVA concentration and in-between the medium to high
levels of the external phase (Fig. 4).
Prediction profiler. – The prediction profiler (Fig. 5) further confirmed the above ob-
servations. Fig. 5 displays prediction traces for each independent variable. A prediction
trace is the predicted response obtained when one variable changes while the others are
held constant at current values. Prediction profiles are especially useful in multiple-re-
sponse models to help evaluate the factors helpful in optimizing an experimental de-
sign. Fig. 5 shows that it is possible to achieve the optimum size of 134.24 nm and encap-
sulation efficiency (EE) of 88.8 %, with desirability of 0.95 on the scale of 0 to 1, where 0
is not acceptable and 1 is the desirable response. Optimized independent variables were
48.2:61.8, 0.321 (%, m/V) and 263 mL for X1, X2 and X3, respectively. Checkpoint analysis
with this optimal condition analysis gave a mean size of 144.4 ± 16 nm (n = 3) and a
mean residual of 10.16 nm with 90.1 % EE. The size range of the optimal formula was
similar to that of sample No. 9 of the BBD design, as shown by the dynamic light scatter-
ing data in Table II and morphologically in Fig. 1a.
Physical meaning of statistical analysis. – The Pareto plot analysis, regression models,
contour profiles and the prediction profiler gave predictable results about the effects on
the responses due to individual and combined factors. From the Pareto plot, we dedu-
ced the nature of the relationship between the responses and the individual factors,
which are significant. The particle size varies curvilinearly with PVA (%, m/V) and exter-
nal phase volume, so the medium value of the parameter would give the desired re-
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Fig. 5. Prediction and desirability plot
of the reduced model showing the ef-
fect of polymer ratio (X1), concentra-
tion PVA (X2) and volume of the exter-
nal phase (X3) on the particle size of
heparin-loaded nanoparticles.
sponse. Eq. (2) and Pareto plot (Fig. 3) showed that the influence of the polymer percent-
age ratio (X1) was not significant, either alone or when combined with the external
phase volume (X1X3). This may be explained by the fact that the various polymer ratios
utilized in the study behaved in a similar way. The potential charge density effect, re-
lated to the different charges provided by the different levels of E-RLPO that were incor-
porated, might have been overridden by the steric effect of the PLGA.
Although polymer concentration is known to have an increasing effect on the diam-
eter size, the levels of PVA concentration and external phase volume when used in com-
bination, were found to minimize the effects on the particle size. Polymer concentration
in the internal phase of the emulsion is an important factor due to its significant increas-
ing effect on the particle size, but this effect was moderated by PVA concentration. This
data may be explained by the fact that increasing viscosity of the dispersed phase leads
to coarser dispersion of polymer solution into the aqueous phase (13). This could result
from increased resistance due to the flow and shear stress during emulsification. Inade-
quate distribution of the phases during emulsification would produce an unstable emul-
sion, resulting in larger particle sizes and higher polydispersity (14).
In this study, PVA was used as an emulsion stabilizer. The amount of emulsion sta-
bilizer plays an important role in the emulsification process and in the protection of
droplets, because it can prevent coalescence of globules before particle hardening (14).
The concentration of PVA clearly affects the particle size, although the effect partly de-
pends on polymer ratio and external phase volume. At lower concentrations, the num-
ber of PVA macromolecules is not adequate to stabilize the emulsion. The resultant
emulsion has coarser droplets and is more polydisperse. At higher PVA concentrations,
the amount of residual PVA associated with the nanoparticles increased (13), leading to
aggregation of the particles. This may be due to the interlocking of PVA and PLGAmole-
cules during particle formation.
The external phase volume plays an important role in the formation and stability of
the double emulsion system. With an increase in the external phase volume, the droplet
size of the secondary emulsion decreases because of a decrease in the frequency of colli-
sion/coalescence of droplets, though the amount of decrease depends on the level of
PVA concentration. This may also be explained by the Oswald ripening process (15), in
which small particles shrink due to enhanced solubility arising from their high curva-
ture while larger particles grow.
CONCLUSIONS
The statistical analysis based on BBD design provided the best data fit to the regres-
sion formula containing significant factor coefficients that predicted particle diameter
values (after freeze-drying). The values of independent variables for the above predicted
responses were 48.2:61.8 (PLGA:E-RLPO), 0.321 (PVA %, m/V), 263 mL (external phase
volume) and are in agreement with the results obtained from the contour profiler, check-
point analysis and the Pareto plot.
The nanosystem was found to be robust with respect to the percentage of drug en-
capsulation. Future studies should also include the development of predictive mathe-
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matical models relating the influence of process parameters and other factors that may
affect nanoparticle characteristics (e.g., size, drug encapsulation, and drug release and
stability). Some of these process parameters and factors include the rate and speed of
stirring, polymer molecular mass, internal/external phase ratio, operation temperature,
and the method of solvent removal. In addition, it would be interesting to study the
amount and type of residual emulsion stabilizers associated with nanoparticles, and
their effect on the physico-chemical properties of the particles themselves.
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S A @ E T A K
Statisti~ka analiza nanokapsuliranja niskomolekularnog heparina
VAISHNAVI GANTI, ABEBE ENDALE MENGESHA, JACOB MARSZALEK i BI-BOTTI C. YOUAN
Box-Behnkenovo dizajniranje (BBD) primijenjeno je za pra}enje utjecaja formulacij-
skih varijabli na svojstva nano~estica (NP) s heparinom. Za izradu nano~estica kori{ten
je kopolimer mlije~ne i glikolne kiseline (PLGA) i polimetakrilat-RLPO (E-RLPO). Nano-
~estice su pripravljene metodom dvostruke evaporacije otapala iz emulzije. Nezavisne
varijable bile su: X1 – omjer masa polimera (PLGA : E-RLPO) u uljnoj fazi, X2 – koncen-
tracija polivinil alkohola (PVA) kao stabilizatora emulzije i X3 – volumen vanjske vode-
ne faze (W2). Zavisne varijable bile su veli~ina ~estica (analizirana pomo}u dinami~kog
rasapa svjetlosti) i u~inkovitost inkapsuliranja (EE) (pra}ena spektrofotometrijski). Polinom-
ska jednad`ba dobivena regresijskom analizom reduciranog modela odli~no je odgova-
rala (p = 0,0002, F = 25,7952 i R2 = 0,96). Optimalna veli~ina nano~estica bila je 134,2 ±
16,5 nm s formulacijskim varijablama 48,2:61,8, 0,321 (%, m/V) i 263 mL for X1, X2 od-
nosno X3. Vjerojatno je zbog elektrostatskih interakcija izme|u negativno nabijene ljeko-
vite tvari i pozitivno nabijenog E-RLPO u~inkovitost inkapsuliranja heparina varirala od
74,4 ± 6,5 % (najni`a vrijednost) do 92,1 ± 5,3 % (najvi{a vrijednost). Rezultati sugeriraju
da je BBD vrlo korisno u racionalnom dizajniranju nano~estica s heparinom.
Klju~ne rije~i: heparin, nano~estica, stupanj inkapsuliranja, Box-Behnkenovo dizajniranje
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